Media Center

Alfasigma announces the Completion of Marketing Authorisation Transfer for Jyseleca® in the European Union

Alfasigma completes transaction to acquire the Jyseleca® business from Galapagos for up to €170 million

Alfasigma signs an agreement to acquire Jyseleca® business for up to €170 million from Galapagos following October letter of intent

Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.

Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.

Alfasigma signs a letter of intent to acquire the Jyseleca® business from Galapagos, expanding its European presence through an innovative product specializing in the rheumatology and gastrointestinal areas